多西紫杉醇联合顺铂与联合奈达铂化疗方案治疗晚期非小细胞肺癌的临床观察

《多西紫杉醇联合顺铂与联合奈达铂化疗方案治疗晚期非小细胞肺癌的临床观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、万方数据新疆医科大学学报JOURNAI，oFXINJIANGMEDICAl。UNTVERSITY2009Jul．，32(7)901多西紫杉醇联合顺铂与联合奈达铂化疗方案治疗晚期非小细胞肺癌的临床观察王强‘，单利”(新疆医科大学附属肿瘤医院内一科．新疆乌鲁木齐830011)摘要：目的：观察多西紫杉醇联合顺铂化疗方案与多西紫杉醇联合奈达铂方案治疗中晚期(III。、Ⅳ期)非小细胞肺癌(nonsmallcelllungcancer。NSCLC)的疗效及不良反应。方法：62例中晚期非小细胞肺癌患者，其中多西紫杉醇联合顺铂化疗方案组(A组)32例，多西紫杉醇联合奈达铂方案组(B组

2、)30例。结果：A组有效率(37．5％)B组有效率(38．7％)无显著差异(P>O．05)；A组胃肠道反应(77．4％)发生率明显高于B组(60％)(P

3、码：A文章编号：1009—5551(2009)07—0901—04Clinicalobservationoftheregimenfordocetaxelcombinedwithcisplatinanddedaplainchemotherapyinthetreatmentofadvancednon’smallcelllungcancerWANGQiang，SHANLi(FirstDepartmentofMedicalOncology，AffiliatedTumorHospital，XinjiangMedicalUniversity，Urumqi830011，China)

4、Abstract：Objective：TodetecttheefficacyandthesideeffectoftheregimenfordocetaxelcombinedwithcisplatinandNedaplatinchemotherapyinthetreatmentwithadvancednon—smallcelllungcancer．Meth—ods：AtotaIof62patientswithadvancednon-smallcelllungcancerweredividedintothedocetaxeIcorn—binedwithcisplating

5、roup(groupA，n一32)andthedocetaxelcombinedwithNedaplatingroup(groupB72—30)．Results：TheefficacyofgroupAwas37．5％andgroupBwas38．7％，therewasnosignificantdifferencebetweenthetwogroupsincurativeeffect(P>O．05)．Ahigherresponserateofdigestivereac—tionandnephrotoxicity(77．4％)occurredingroupA，compar

6、edtOthatoccurredingroupB(60％)，withasignificantdifferencebetweenthetwogroups(P<0．01)．TherewasnosignificantdifferencebetweentWOgroupsinthetoxicityofkidney．Therewasalowerincidenceofleucopeniaresponserate(50％)ingroupAthaningroupB(76．67％)，withasignificantdifferencebetweenthegroups(P

7、erewasalowerthrombocytopeniaresponserate(6．3％)ingroupAthaningroupB(26．67oA)，withasignifi—cantdifferencebetweenthegroups(P